Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 549

Results For "MED"

6285 News Found

Moderna seeks approval from EMA for its Covid-19 vaccine for children between 6-11 years
News | November 10, 2021

Moderna seeks approval from EMA for its Covid-19 vaccine for children between 6-11 years

The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11


Lupin partners with Shaan to raise awareness on mental health
Healthcare | November 10, 2021

Lupin partners with Shaan to raise awareness on mental health

Shaan’s hit song `Tanha Dil Tanha Safar relaunched


Pulmatrix resolves dispute with Cipla
News | November 10, 2021

Pulmatrix resolves dispute with Cipla

Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.


India Pharmaceutical Market grows 5% in October 2021
News | November 10, 2021

India Pharmaceutical Market grows 5% in October 2021

Ind-Ra continues to expect IPM’s revenue to grow over 12% yoy in FY22


AstraZeneca Pharma India PAT at Rs 11.94 cr. in Q2FY22
News | November 10, 2021

AstraZeneca Pharma India PAT at Rs 11.94 cr. in Q2FY22

The Board of Directors of AstraZeneca Pharma India have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021


Marksons Pharma PAT slips to Rs 46.28 in Q2FY22
News | November 10, 2021

Marksons Pharma PAT slips to Rs 46.28 in Q2FY22

Marksans Pharma has reported consolidated financial results for the period ended September 30, 2021


Takeda receives the Arogaya CIBioD Leadership Award
Public Health | November 10, 2021

Takeda receives the Arogaya CIBioD Leadership Award

It was recognized for its holistic initiatives designed to improve the quality of life and standards of care for patients


Strides Pharma Science incurs Rs 162.55 cr. loss in Q2FY22
News | November 10, 2021

Strides Pharma Science incurs Rs 162.55 cr. loss in Q2FY22

Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021


Wockhardt PAT at Rs 33.53 cr. in Q2FY22
News | November 09, 2021

Wockhardt PAT at Rs 33.53 cr. in Q2FY22

The Board of Directors of Wockhardt have approved the unaudited consolidated financial results for the period ended September 30, 2021.


Bristol Myers neoadjuvant Opdivo (nivolumab) plus chemotherapy assists cancer patients effectively
Biotech | November 09, 2021

Bristol Myers neoadjuvant Opdivo (nivolumab) plus chemotherapy assists cancer patients effectively

Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma